Osimertinib activates a TGF-beta2-dependent secretory program that drives lung adenocarcinoma progression. Ghosh M, Wu C, Kumar A, Nilsson M, et al. J Clin Invest 2025;136:e198418.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ghosh M, Wu C, Kumar A, Nilsson M, et al. Osimertinib activates a TGF-beta2-dependent secretory program that drives lung adenocarcinoma progression. J Clin Invest 2025;136:e198418.
PMID: 41364502